Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 182 articles:
HTML format
Text format



Single Articles


    August 2017
  1. THALMANN GN, Nguyen DP
    Sentinel nodes in prostate cancer- are we chasing a ghost?
    BJU Int. 2017;120:161-162.
    PubMed     Text format    



  2. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: (c) NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int. 2017;120:168-184.
    PubMed     Text format    


  3. GORIN MA, Pomper MG, Pienta KJ, Rowe SP, et al
    Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer.
    BJU Int. 2017;120:160-161.
    PubMed     Text format    


    July 2017
  4. BASOURAKOS SP, Davis JW, Chapin BF, Ward JF, et al
    Baseline and Longitudinal Plasma Caveolin-1 Level as a Biomarker in Active Surveillance for Early Stage Prostate Cancer.
    BJU Int. 2017 Jul 15. doi: 10.1111/bju.13963.
    PubMed     Text format     Abstract available


  5. DESS RT, Hartman HE, Aghdam N, Jackson WC, et al
    Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer.
    BJU Int. 2017 Jul 15. doi: 10.1111/bju.13962.
    PubMed     Text format     Abstract available


  6. LANGLEY SEM, Soares R, Uribe J, Uribe-Lewis S, et al
    Long-term oncological outcomes and toxicity in 597 men </=60 years of age at time of low dose rate brachytherapy for localised prostate cancer.
    BJU Int. 2017 Jul 3. doi: 10.1111/bju.13946.
    PubMed     Text format     Abstract available


  7. BASOURAKOS SP, Hoffman K, Kim J
    Active surveillance in prostate cancer: new efforts, new voices, new hope.
    BJU Int. 2017;120:4-5.
    PubMed     Text format    


    June 2017
  8. DE BRUYCKER A, Lambert B, Claeys T, Delrue L, et al
    Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
    BJU Int. 2017 Jun 24. doi: 10.1111/bju.13938.
    PubMed     Text format     Abstract available


  9. SOORIAKUMARAN P
    Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone: a randomised controlled feasibility trial.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13925.
    PubMed     Text format     Abstract available


  10. TUMATI V, Jackson WC, Abugharib AE, Raj G, et al
    Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13926.
    PubMed     Text format     Abstract available


  11. VILLERS A, Flamand V, Arquimedes RC, Puech P, et al
    Robot-assisted partial prostatectomy for anterior prostate cancer: a step-by-step guide.
    BJU Int. 2017;119:968-974.
    PubMed     Text format     Abstract available


  12. DIOLOMBI ML, Epstein JI
    Metastatic potential to regional lymph nodes with Gleason score </=7, including tertiary pattern 5, at radical prostatectomy.
    BJU Int. 2017;119:872-878.
    PubMed     Text format     Abstract available


    May 2017
  13. HEDDEN L, Wassersug R, Mahovlich S, Pollock P, et al
    Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners.
    BJU Int. 2017 May 17. doi: 10.1111/bju.13885.
    PubMed     Text format     Abstract available


  14. CHIU PKF, Alberts AR, Venderbos LDF, Bangma CH, et al
    Additional benefit of using a risk based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    BJU Int. 2017 May 12. doi: 10.1111/bju.13913.
    PubMed     Text format     Abstract available


  15. TOSOIAN JT, Chappidi MR, Bishoff JT, Freedland SJ, et al
    Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with NCCN Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13911.
    PubMed     Text format     Abstract available


  16. ZUMSTEG ZS, Zelefsky MJ, Woo KM, Spratt DE, et al
    Unification of favorable intermediate, unfavorable intermediate, and very high risk-stratification criteria for prostate cancer.
    BJU Int. 2017 May 2. doi: 10.1111/bju.13903.
    PubMed     Text format     Abstract available


  17. GANDAGLIA G, Fossati N, Dell'Oglio P, Montorsi F, et al
    Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?
    BJU Int. 2017;119:652-653.
    PubMed     Text format    


  18. TOSOIAN JJ, Chappidi M, Feng Z, Humphreys EB, et al
    Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    BJU Int. 2017;119:676-683.
    PubMed     Text format     Abstract available


    April 2017
  19. PROTOPAPA E, van der Meulen J, Moore CM, Smith SC, et al
    Patient Reported Outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13896.
    PubMed     Text format     Abstract available


  20. PARSONS JK, Pierce JP, Mohler J, Paskett E, et al
    The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13890.
    PubMed     Text format     Abstract available


  21. CHIEN GW, Slezak JM, Harrison TN, Jung H, et al
    Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population.
    BJU Int. 2017 Apr 19. doi: 10.1111/bju.13843.
    PubMed     Text format     Abstract available


  22. CRAWLEY D, Garmo H, Rudman S, Stattin P, et al
    Association between Type 2 diabetes, curative treatment and survival in men with intermediate and high risk localised prostate cancer.
    BJU Int. 2017 Apr 18. doi: 10.1111/bju.13880.
    PubMed     Text format     Abstract available


  23. VIOLET JA, Hofman MS
    Prostate specific membrane antigen (PSMA) from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.
    BJU Int. 2017 Apr 5. doi: 10.1111/bju.13871.
    PubMed     Text format     Abstract available


  24. EMBERTON M
    An end to the phenomenon of 'upgrading' in early prostate cancer?
    BJU Int. 2017;119:506-507.
    PubMed     Text format    


    March 2017
  25. TELANG JM, Lane BR, Cher ML, Miller DC, et al
    Prostate cancer, family history, and eligibility for active surveillance: A systematic review of the literature.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13862.
    PubMed     Text format     Abstract available


  26. DIJKSTRA S, Govers TM, Hendriks RJ, Schalken JA, et al
    Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13861.
    PubMed     Text format     Abstract available


  27. GROGAN J, Gupta R, Mahon KL, Stricker PD, et al
    Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in radical prostatectomy patients with long-term follow up.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13857.
    PubMed     Text format     Abstract available


  28. HOWARD LE, Moreira D, De Hoedt A, Aronson WJ, et al
    Cut-points for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13856.
    PubMed     Text format     Abstract available


  29. CLEMENT-ZHAO A, Auvray M, Aboudagga H, Blanc-Durand F, et al
    Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13855.
    PubMed     Text format     Abstract available


  30. MACLENNAN S, Williamson PR, Bekema H, Campbell M, et al
    A core outcome set for localised prostate cancer effectiveness trials.
    BJU Int. 2017 Mar 27. doi: 10.1111/bju.13854.
    PubMed     Text format     Abstract available


  31. KANDASWAMY GV, Bennett A, Narahari K, Hughes O, et al
    Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate risk localised prostate cancer - results from a large contemporaneous cohort.
    BJU Int. 2017 Mar 20. doi: 10.1111/bju.13850.
    PubMed     Text format     Abstract available


  32. KANTHABALAN A, Peters M, Van Vulpen M, McCartan N, et al
    Focal Salvage HIFU in radiorecurrent prostate cancer.
    BJU Int. 2017 Mar 4. doi: 10.1111/bju.13831.
    PubMed     Text format     Abstract available


  33. BALL MW, Harris KT, Schwen ZR, Mullins JK, et al
    Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series.
    BJU Int. 2017;119:444-448.
    PubMed     Text format     Abstract available


    February 2017
  34. SPAHN M, Morlacco A, Boxler S, Joniau S, et al
    Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: A multi-institutional study of 62 patients.
    BJU Int. 2017 Feb 20. doi: 10.1111/bju.13818.
    PubMed     Text format     Abstract available


  35. VAN LEEUWEN PJ, Hayen A, Thompson JE, Moses D, et al
    A Multiparametric Magnetic Resonance Imaging Based Risk Model to Determine the Risk of Significant Prostate Cancer prior to biopsy.
    BJU Int. 2017 Feb 16. doi: 10.1111/bju.13814.
    PubMed     Text format     Abstract available


  36. HAWKEN SR, Auffenberg GB, Miller DC, Lane BR, et al
    Calculating Life Expectancy to Inform Prostate Cancer Screening and Treatment Decisions.
    BJU Int. 2017 Feb 15. doi: 10.1111/bju.13812.
    PubMed     Text format     Abstract available


  37. VAN DER POEL HG, Wit EM, Acar C, van den Berg NS, et al
    Sentinel node biopsy for prostate cancer: report from a consensus panel meeting.
    BJU Int. 2017 Feb 10. doi: 10.1111/bju.13810.
    PubMed     Text format     Abstract available


  38. MURPHY DG, Hofman M, Lawrentschuk N, Maurer T, et al
    Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer.
    BJU Int. 2017;119:194-195.
    PubMed     Text format    


  39. FICARRA V, Crestani A, Rossanese M, Palumbo V, et al
    Urethral-fixation technique improves early urinary continence recovery in patients who undergo retropubic radical prostatectomy.
    BJU Int. 2017;119:245-253.
    PubMed     Text format     Abstract available


  40. MATHIEU R, Lucca I, Vartolomei MD, Mbeutcha A, et al
    Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.
    BJU Int. 2017;119:234-238.
    PubMed     Text format     Abstract available


  41. WASHINO S, Okochi T, Saito K, Konishi T, et al
    Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients.
    BJU Int. 2017;119:225-233.
    PubMed     Text format     Abstract available


    January 2017
  42. MISRA-HEBERT AD, Hu B, Klein EA, Stephenson A, et al
    Prostate Cancer Screening Practices in a Large, Integrated Health System: 2007-2014.
    BJU Int. 2017 Jan 31. doi: 10.1111/bju.13793.
    PubMed     Text format     Abstract available


  43. SHIN T, Smyth TB, Ukimura O, Ahmadi N, et al
    Detection of Prostate Cancer Using Magnetic Resonance Imaging/Ultrasonography Fusion Targeted Biopsy in African-American Men.
    BJU Int. 2017 Jan 23. doi: 10.1111/bju.13786.
    PubMed     Text format     Abstract available


  44. PELLEGRINI KL, Sanda MG, Patil D, Long Q, et al
    Evaluation of a 24-Gene Signature for Prognosis of Metastatic Events and Prostate Cancer-Specific Mortality.
    BJU Int. 2017 Jan 20. doi: 10.1111/bju.13779.
    PubMed     Text format     Abstract available


  45. FAN L, Wang Y, Chenfei C, Pan J, et al
    Chromogranin A and neurone-specific enolase variations during the first three months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Jan 20. doi: 10.1111/bju.13781.
    PubMed     Text format     Abstract available


  46. TRABULSI EJ, Tripathi SK, Gomella L, Solomides C, et al
    Development of a Voided Urine Assay for Detecting Prostate Cancer Noninvasively: A Pilot Study.
    BJU Int. 2017 Jan 11. doi: 10.1111/bju.13775.
    PubMed     Text format     Abstract available


  47. CROUZET S, Blana A, Murat FJ, Pasticier G, et al
    Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients.
    BJU Int. 2017 Jan 7. doi: 10.1111/bju.13766.
    PubMed     Text format     Abstract available


  48. POORTHUIS MH, Vernooij RW, van Moorselaar RJ, de Reijke TM, et al
    First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ten randomised clinical trials.
    BJU Int. 2017 Jan 6. doi: 10.1111/bju.13764.
    PubMed     Text format     Abstract available


  49. TOSOIAN JJ, Druskin SC, Andreas D, Mullane P, et al
    Prostate health index density improves detection of clinically-significant prostate cancer.
    BJU Int. 2017 Jan 6. doi: 10.1111/bju.13762.
    PubMed     Text format     Abstract available


  50. RESCIGNO P, Rodrigues DN, de Bono JS
    Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge.
    BJU Int. 2017;119:3-4.
    PubMed     Text format    


  51. SANTOK GD, Abdel Raheem A, Kim LH, Chang K, et al
    Perioperative and short-term outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy stratified by gland size.
    BJU Int. 2017;119:135-141.
    PubMed     Text format     Abstract available


  52. ZARGAR H, van den Bergh R, Moon D, Lawrentschuk N, et al
    The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    BJU Int. 2017;119:110-115.
    PubMed     Text format     Abstract available


  53. DANNEMAN D, Drevin L, Delahunt B, Samaratunga H, et al
    Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012.
    BJU Int. 2017;119:50-56.
    PubMed     Text format     Abstract available


  54. PARK SY, Oh YT, Jung DC, Cho NH, et al
    Diffusion-weighted imaging predicts upgrading of Gleason score in biopsy-proven low grade prostate cancers.
    BJU Int. 2017;119:57-66.
    PubMed     Text format     Abstract available


    December 2016
  55. GHADJAR P, Hayoz S, Genitsch V, Zwahlen DR, et al
    Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.
    BJU Int. 2016 Dec 17. doi: 10.1111/bju.13742.
    PubMed     Text format     Abstract available


  56. ALBISINNI S, Artigas C, Aoun F, Biaou I, et al
    Clinical impact of 68 Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    BJU Int. 2016 Dec 15. doi: 10.1111/bju.13739.
    PubMed     Text format     Abstract available


  57. DE CASTRO ABREU AL, Fay CE, Park D, Quinn D, et al
    Robotic Salvage Retroperitoneal and Pelvic Lymph Node Dissection for "Node-only" Recurrent Prostate Cancer: Technique and Initial Series.
    BJU Int. 2016 Dec 15. doi: 10.1111/bju.13741.
    PubMed     Text format     Abstract available


  58. WANG LL, Wallis CJ, Sathianathen N, Lawrentschuk N, et al
    ProtecTion from overtreatment - does a randomised trial finally answer the key question in localised prostate cancer?
    BJU Int. 2016 Dec 8. doi: 10.1111/bju.13734.
    PubMed     Text format     Abstract available


    November 2016
  59. GNANAPRAGASAM VJ, Warren AY
    Improving clinical prognostic stratification models for men with prostate cancer: a practical step closer to more individualised care without added costs.
    BJU Int. 2016 Nov 22. doi: 10.1111/bju.13721.
    PubMed     Text format     Abstract available


  60. RAUSCHER I, Duwel C, Wirtz M, Schottelius M, et al
    Value of 111 In-PSMA-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.
    BJU Int. 2016 Nov 10. doi: 10.1111/bju.13713.
    PubMed     Text format     Abstract available


  61. HERDEN J, Heidenreich A, Weissbach L
    Risk Stratification - a Tool to predict the Course of Active Surveillance for Localized Prostate Cancer?
    BJU Int. 2016 Nov 10. doi: 10.1111/bju.13715.
    PubMed     Text format     Abstract available


  62. ESCH L, Fahlbusch M, Albers P, Hautzel H, et al
    11C-acetate PET/CT imaging for detection of recurrent disease following radical prostatectomy or radiotherapy in patients with prostate cancer.
    BJU Int. 2016 Nov 8. doi: 10.1111/bju.13706.
    PubMed     Text format     Abstract available


  63. POYET C, Hermanns T
    Prostate cancer risk calculators: still much work ahead.
    BJU Int. 2016;118:670-671.
    PubMed     Text format    


  64. ROCCO B, Boeri L
    Prostate cancer gene 3 assay in the magnetic resonance imaging (MRI)/ultrasonography fusion target biopsy era: a future to believe in.
    BJU Int. 2016;118:672-673.
    PubMed     Text format    


  65. DE LUCA S, Passera R, Cattaneo G, Manfredi M, et al
    High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy af
    BJU Int. 2016;118:723-730.
    PubMed     Text format     Abstract available


    October 2016
  66. GILBERT DC, Duong T, Kynaston HG, Alhasso AA, et al
    Quality of life outcomes from the PATCH trial evaluating LHRH agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
    BJU Int. 2016 Oct 18. doi: 10.1111/bju.13687.
    PubMed     Text format     Abstract available


  67. TILKI D, Preisser F, Tennstedt P, Tober P, et al
    Adjuvant radiation therapy is associated with better oncological outcome compared to salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy.
    BJU Int. 2016 Oct 15. doi: 10.1111/bju.13679.
    PubMed     Text format     Abstract available


  68. LOEB S, Shin SS, Broyles DL, Wei JT, et al
    Prostate Health Index (phi) Improves Multivariable Risk Prediction of Aggressive Prostate Cancer.
    BJU Int. 2016 Oct 15. doi: 10.1111/bju.13676.
    PubMed     Text format     Abstract available


  69. CORFIELD J, Crozier J, Joshua A, Bolton D, et al
    Understanding the role of new systemic agents in the treatment of prostate cancer.
    BJU Int. 2016 Oct 6. doi: 10.1111/bju.13633.
    PubMed     Text format     Abstract available


  70. COONEY KA, Beebe-Dimmer JL
    HOXB13 mutations and prostate cancer risk.
    BJU Int. 2016;118:496-7.
    PubMed     Text format    


  71. MEREDITH G, Wong D, Yaxley J, Coughlin G, et al
    The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
    BJU Int. 2016;118 Suppl 3:49-55.
    PubMed     Text format     Abstract available


  72. MATARAZA JM, Gotwals P
    Recent advances in immuno-oncology and its application to urological cancers.
    BJU Int. 2016;118:506-14.
    PubMed     Text format     Abstract available


  73. DEVECI S, Gotto GT, Alex B, O'Brien K, et al
    A survey of patient expectations regarding sexual function following radical prostatectomy.
    BJU Int. 2016;118:641-5.
    PubMed     Text format     Abstract available


  74. WYSOCK JS, Mendhiratta N, Zattoni F, Meng X, et al
    Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.
    BJU Int. 2016;118:515-20.
    PubMed     Text format     Abstract available


  75. MURRAY NP, Aedo S, Reyes E, Orellana N, et al
    Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    BJU Int. 2016;118:556-62.
    PubMed     Text format     Abstract available


    September 2016
  76. YAXLEY JW, Lah K, Yaxley JP, Gardiner RA, et al
    Long term outcome of high dose rate (HDR) brachytherapy for intermediate and high risk prostate cancer with a median follow up of 10 years.
    BJU Int. 2016 Sep 15. doi: 10.1111/bju.13659.
    PubMed     Text format     Abstract available


  77. HOFHEINZ RD, Lange C, Ecke T, Kloss S, et al
    Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional QoLiTime study.
    BJU Int. 2016 Sep 12. doi: 10.1111/bju.13658.
    PubMed     Text format     Abstract available


  78. BRANGER N, Maubon T, Traumann M, Thomassin-Piana J, et al
    Is a negative mpMRI really able to rule out significant prostate cancer?: The real life experience.
    BJU Int. 2016 Sep 12. doi: 10.1111/bju.13657.
    PubMed     Text format     Abstract available


  79. LOEB S, Curnyn C, Fagerlin A, Braithwaite RS, et al
    A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.
    BJU Int. 2016 Sep 9. doi: 10.1111/bju.13651.
    PubMed     Text format     Abstract available


  80. MARTORANA E, Pirola GM, Scialpi M, Micali S, et al
    Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with PIRADS score.
    BJU Int. 2016 Sep 8. doi: 10.1111/bju.13649.
    PubMed     Text format     Abstract available


  81. EGEVAD L, Samaratunga H, Srigley JR, Delahunt B, et al
    Consensus guidelines for reporting prostate cancer Gleason Grade.
    BJU Int. 2016;118:E1-2.
    PubMed     Text format    


  82. JOHNSON MH
    Tailored prostate cancer survivorship: one size does not fit all.
    BJU Int. 2016;118:343-4.
    PubMed     Text format    


  83. EHDAIE B
    Active surveillance for prostate cancer: is it too active?
    BJU Int. 2016;118:343.
    PubMed     Text format    


    August 2016
  84. WILLIAMS SB, Chamie K, Duan Z, Hoffman KE, et al
    Risk of Hospitalization Following Primary Treatment for Prostate Cancer.
    BJU Int. 2016 Aug 25. doi: 10.1111/bju.13647.
    PubMed     Text format     Abstract available


  85. MCDANIEL AS, Ferraldeschi R, Krupa R, Landers M, et al
    Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
    BJU Int. 2016 Aug 18. doi: 10.1111/bju.13631.
    PubMed     Text format     Abstract available


  86. BECKMANN KR, O'Callaghan ME, Ruseckaite R, Kinnear N, et al
    Prostate cancer outcomes for men who present with symptoms at diagnosis.
    BJU Int. 2016 Aug 4. doi: 10.1111/bju.13622.
    PubMed     Text format     Abstract available


  87. HANSEN NL, Barrett T, Koo B, Doble A, et al
    The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.
    BJU Int. 2016 Aug 4. doi: 10.1111/bju.13619.
    PubMed     Text format     Abstract available


  88. PATEL VR, Palayapalayam Ganapathi H
    Management dilemmas in low-risk prostate cancer.
    BJU Int. 2016;118:180-1.
    PubMed     Text format    


  89. FLAMIATOS JF, Beer TM, Graff JN, Eilers KM, et al
    COX-2 Inhibition for Prostate Cancer Chemoprevention: Double-Blind Randomized Study of Pre-Prostatectomy Celecoxib or Placebo.
    BJU Int. 2016 Aug 1. doi: 10.1111/bju.13612.
    PubMed     Text format     Abstract available



  90. Abstracts of the 17th Asia-Pacific Prostate Cancer Conference 2016, Australia, 31 August-3 September 2016.
    BJU Int. 2016;118 Suppl 1:6-42.
    PubMed     Text format    



  91. Welcome for APCC BJUi Supplement Embracing a precision approach to prostate cancer.
    BJU Int. 2016;118 Suppl 1:5.
    PubMed     Text format    


    July 2016
  92. MAYER EN, Tward JD, Bassett M, Lenherr SM, et al
    Management of Radiation Therapy Oncology Group (RTOG) grade 4 urinary adverse events (UAEs) from radiotherapy for prostate cancer.
    BJU Int. 2016 Jul 28. doi: 10.1111/bju.13607.
    PubMed     Text format     Abstract available


  93. EMERY JD, Jefford M, King M, Hayne D, et al
    The ProCare Trial: a phase II randomised controlled trial of shared care for follow-up of men with prostate cancer.
    BJU Int. 2016 Jul 19. doi: 10.1111/bju.13593.
    PubMed     Text format     Abstract available


  94. HEGEMANN M, Stenzl A, Bedke J, Chi KN, et al
    Liquid biopsy: ready to guide therapy in advanced prostate cancer?
    BJU Int. 2016 Jul 19. doi: 10.1111/bju.13586.
    PubMed     Text format     Abstract available


  95. LANE JA, Metcalfe C, Young GJ, Peters TJ, et al
    Patient-reported outcomes in the ProtecT randomised trial of clinically localised prostate cancer treatments: design and baseline urinary, bowel and sexual function and quality of life.
    BJU Int. 2016 Jul 14. doi: 10.1111/bju.13582.
    PubMed     Text format     Abstract available


  96. ZHANG BY, Riska SM, Mahoney DW, Costello BA, et al
    Germline Genetic Variation in JAK2 as a Prognostic Marker in Castration Resistant Prostate Cancer.
    BJU Int. 2016 Jul 13. doi: 10.1111/bju.13584.
    PubMed     Text format     Abstract available


  97. DEBRUYNE FM, Behre HM, Roehrborn CG, Maggi M, et al
    Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: Prostate health outcomes in the Registry of Hypogonadism in Men (RHYME).
    BJU Int. 2016 Jul 13. doi: 10.1111/bju.13578.
    PubMed     Text format     Abstract available


  98. LEYH-BANNURAH SR, Abou-Haidar H, Dell'Oglio P, Schiffmann J, et al
    Primary Gleason Pattern Upgrading in contemporary D'Amico low-risk prostate cancer patients: Implications for future biomarkers and imaging modalities.
    BJU Int. 2016 Jul 1. doi: 10.1111/bju.13570.
    PubMed     Text format     Abstract available


    June 2016
  99. ANDRONIS L, Goranitis I, Pirrie S, Pope A, et al
    Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
    BJU Int. 2016 Jun 3. doi: 10.1111/bju.13549.
    PubMed     Text format     Abstract available


  100. ZIETMAN A, Smith J, Klein E, Droller M, et al
    Consensus guidelines for reporting prostate cancer Gleason Grade.
    BJU Int. 2016;117:849.
    PubMed     Text format    


  101. ANDERSON CB, Tin AL, Sjoberg DD, Mulhall JP, et al
    Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  102. DE NUNZIO C, Presicce F, Lombardo R, Cancrini F, et al
    Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  103. DINH KT, Mahal BA, Ziehr DR, Muralidhar V, et al
    Risk of prostate cancer mortality in men with a history of prior cancer.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  104. WATSON E, Shinkins B, Frith E, Neal D, et al
    Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


    May 2016
  105. DE CARVALHO TM, Heijnsdijk EA, de Koning HJ
    Estimating the risks and benefits of Active Surveillance protocols for Prostate Cancer: A microsimulation study.
    BJU Int. 2016 May 25. doi: 10.1111/bju.13542.
    PubMed     Text format     Abstract available


  106. WINTER A, Sirri E, Jansen L, Wawroschek F, et al
    Comparison of prostate cancer survival in Germany and the United States: Can differences be attributed to differences in stage distributions?
    BJU Int. 2016 May 21. doi: 10.1111/bju.13537.
    PubMed     Text format     Abstract available


  107. VAN LEEUWEN PJ, Emmett L, Ho B, Delprado W, et al
    Prospective Evaluation of 68Gallium-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Prostate Cancer.
    BJU Int. 2016 May 21. doi: 10.1111/bju.13540.
    PubMed     Text format     Abstract available


  108. DURAND M, Jain M, Robinson B, Aronowitz E, et al
    Magnetic Resonance Microscopy May Enable Distinction Between Normal Histomorphological Features and Prostate Cancer in the Resected Prostate Gland.
    BJU Int. 2016 May 7. doi: 10.1111/bju.13523.
    PubMed     Text format     Abstract available


  109. RAISON N, Elhage O, Dasgupta P
    Getting Personal with Prostate Cancer: DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    BJU Int. 2016 May 7. doi: 10.1111/bju.13522.
    PubMed     Text format     Abstract available


  110. PATEL U, Dasgupta P, Challacombe B, Cahill D, et al
    Pre-biopsy 3T MRI and targeted biopsy of the index prostate cancer - correlation with robot assisted radical prostatectomy.
    BJU Int. 2016 May 7. doi: 10.1111/bju.13525.
    PubMed     Text format     Abstract available


  111. GORIN MA, Pomper MG, Rowe SP
    PSMA-targeted imaging of prostate cancer: the best is yet to come.
    BJU Int. 2016;117:715-6.
    PubMed     Text format    


  112. CUSSANS A, Somani BK, Basarab A, Dudderidge TJ, et al
    The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review.
    BJU Int. 2016;117:725-31.
    PubMed     Text format     Abstract available


    April 2016
  113. FODOR A, Berardi G, Fiorino C, Picchio M, et al
    Toxicity and efficacy of salvage 11C-Choline PET/CT-guided radiation therapy in patients with prostate cancer lymph nodal recurrence.
    BJU Int. 2016 Apr 22. doi: 10.1111/bju.13510.
    PubMed     Text format     Abstract available


  114. BOKHORST LP, Zappa M, Carlsson SV, Kwiatkowski M, et al
    Correlation between stage shift and differences in mortality in the European Randomized study of Screening for Prostate Cancer (ERSPC).
    BJU Int. 2016 Apr 22. doi: 10.1111/bju.13505.
    PubMed     Text format     Abstract available


  115. WHITING PF, Moore TH, Jameson CM, Davies P, et al
    Symptomatic and quality of life outcomes following treatment for clinically localized prostate cancer: a systematic review.
    BJU Int. 2016 Apr 18. doi: 10.1111/bju.13499.
    PubMed     Text format     Abstract available


  116. SELKIRK CG, Helfand BT
    To PSA or not to PSA? Still a question for men with a family history of prostate cancer.
    BJU Int. 2016;117:545.
    PubMed     Text format    


  117. ERNSTMANN N, Weissbach L, Herden J, Winter N, et al
    Patient-physician-communication and health related quality of life of localized prostate cancer patients undergoing radical prostatectomy - a longitudinal multilevel analysis.
    BJU Int. 2016 Apr 1. doi: 10.1111/bju.13495.
    PubMed     Text format     Abstract available


  118. WONG LM, Tang V, Peters J, Costello A, et al
    Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.
    BJU Int. 2016;117 Suppl 4:82-7.
    PubMed     Text format     Abstract available


  119. DELAHUNT B, Egevad L, Grignon DJ, Srigley JR, et al
    Prostate cancer grading: recent developments and future directions.
    BJU Int. 2016;117 Suppl 4:7-8.
    PubMed     Text format    


  120. LAWRENTSCHUK N
    PSA testing and early management of test-detected prostate cancer- consensus at last.
    BJU Int. 2016;117 Suppl 4:5-6.
    PubMed     Text format    


  121. RASTINEHAD AR, Durand M
    A comparison of magnetic resonance imaging and ultrasonography (MRI/US)-fusion guided prostate biopsy devices: too many uncontrolled variables.
    BJU Int. 2016;117:548-9.
    PubMed     Text format    


  122. CULIG Z
    New possibilities for urinary molecular diagnostics.
    BJU Int. 2016;117:547-8.
    PubMed     Text format    


  123. SUN M, Trinh QD
    A Surveillance, Epidemiology and End Results (SEER) database malfunction: perceptions, pitfalls and verities.
    BJU Int. 2016;117:551-2.
    PubMed     Text format    


  124. SELES M, Gutschi T, Mayrhofer K, Fischereder K, et al
    Sampling of the anterior apical region results in increased cancer detection and upgrading in transrectal repeat saturation biopsy of the prostate.
    BJU Int. 2016;117:592-7.
    PubMed     Text format     Abstract available


  125. KAMRAVA M, Hegde JV, Abgaryan N, Chang E, et al
    Does the addition of targeted prostate biopsies to standard systemic biopsies influence treatment management for radiation oncologists?
    BJU Int. 2016;117:584-91.
    PubMed     Text format     Abstract available


  126. ANG M, Rajcic B, Foreman D, Moretti K, et al
    Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    BJU Int. 2016;117 Suppl 4:68-75.
    PubMed     Text format     Abstract available


  127. CHEN EC, Papa N, Lawrentschuk N, Bolton D, et al
    Incidence and risk factors of venous thromboembolism after pelvic uro-oncologic surgery--a single center experience.
    BJU Int. 2016;117 Suppl 4:50-3.
    PubMed     Text format     Abstract available


    March 2016
  128. HAGGSTROM C, Stattin P, Stocks T, Garmo H, et al
    Interpretation of conventional survival analysis and competing risk analysis: An example of hypertension and prostate cancer.
    BJU Int. 2016 Mar 31. doi: 10.1111/bju.13494.
    PubMed     Text format     Abstract available


  129. HECK MM, Thaler MA, Schmid SC, Seitz AK, et al
    Chromogranin A and neuron-specific enolase serum levels as predictors of treatment outcome in metastatic castration-resistant prostate cancer patients under abiraterone therapy.
    BJU Int. 2016 Mar 31. doi: 10.1111/bju.13493.
    PubMed     Text format     Abstract available


  130. SPRATT DE, Cole AI, Palapattu GS, Weizer AZ, et al
    Independent Surgical Validation of the New Prostate Cancer Grade Grouping System.
    BJU Int. 2016 Mar 24. doi: 10.1111/bju.13488.
    PubMed     Text format     Abstract available


  131. SHIOTA M, Yokomizo A, Takeuchi A, Kiyoshima K, et al
    Steroid co-introduction with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
    BJU Int. 2016 Mar 17. doi: 10.1111/bju.13483.
    PubMed     Text format     Abstract available


  132. SHORE ND, Chu F, Moul J, Saltzstein D, et al
    ATRIGEL polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate levels of testosterone in four open label studies in advanced prostate cancer patients.
    BJU Int. 2016 Mar 17. doi: 10.1111/bju.13482.
    PubMed     Text format     Abstract available


  133. BORKOWETZ A, Platzek I, Toma M, Renner T, et al
    Direct comparison of multiparametric MRI and final histopathology in patients with proven prostate cancer in MRI/Ultrasound-fusion biopsy.
    BJU Int. 2016 Mar 2. doi: 10.1111/bju.13461.
    PubMed     Text format     Abstract available


  134. COLE AP, Leow JJ, Trinh QD
    New evidence from the Prostate Cancer Prevention Trial may exculpate cyclooxygenase (COX) blockers in erectile dysfunction.
    BJU Int. 2016;117:385-6.
    PubMed     Text format    


  135. LUNDON DJ
    Prostate cancer risk prediction and the persistence of uncertainty.
    BJU Int. 2016;117:382.
    PubMed     Text format    


  136. ROOBOL MJ
    Where we are with screening and risk prediction for prostate cancer in 2016.
    BJU Int. 2016;117:381.
    PubMed     Text format    


  137. LOEB S
    Prostate biopsy decisions: one-size-fits-all approach with total PSA is out and a multivariable approach with the Prostate Health Index is in.
    BJU Int. 2016;117:383.
    PubMed     Text format    


  138. NAMIKI S, Mitsuzuka K, Kaiho Y, Yamada S, et al
    Serum luteinizing hormone concentration is significantly associated with recovery of urinary function after radical prostatectomy.
    BJU Int. 2016;117:450-5.
    PubMed     Text format     Abstract available


  139. MAI Z, Yan W, Zhou Y, Zhou Z, et al
    Transperineal template-guided prostate biopsy: 10 years of experience.
    BJU Int. 2016;117:424-9.
    PubMed     Text format     Abstract available


    February 2016
  140. DE LA TAILLE A, Martinez-Pineiro L, Cabri P, Houchard A, et al
    Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen deprivation therapy.
    BJU Int. 2016 Feb 25. doi: 10.1111/bju.13455.
    PubMed     Text format     Abstract available


  141. VAN DIE MD, Bone KM, Emery J, Williams SG, et al
    Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.
    BJU Int. 2016 Feb 22. doi: 10.1111/bju.13361.
    PubMed     Text format     Abstract available


  142. GOODALL PP, Little J, Robinson E, Trimble I, et al
    Initial experience of an algorithm-based protocol for the community follow-up of men with prostate cancer.
    BJU Int. 2016 Feb 15. doi: 10.1111/bju.13446.
    PubMed     Text format     Abstract available


  143. EVANS SM, Nag N, Roder D, Brooks A, et al
    Development of an International Prostate Cancer Outcomes Registry.
    BJU Int. 2016 Feb 15. doi: 10.1111/bju.13258.
    PubMed     Text format     Abstract available


  144. CARLSSON S, Jaderling F, Wallerstedt A, Nyberg T, et al
    Oncologic and functional outcomes one year after radical prostatectomy for very low risk prostate cancer. Results from the prospective LAPPRO trial.
    BJU Int. 2016 Feb 11. doi: 10.1111/bju.13444.
    PubMed     Text format     Abstract available


  145. JEFFERIES ER, Bahl A, Hounsome L, Eylert MF, et al
    Admissions to hospital due to fracture in England in prostate cancer patients treated with Androgen Deprivation Therapy (ADT) - do we have to worry about the hormones?
    BJU Int. 2016 Feb 6. doi: 10.1111/bju.13441.
    PubMed     Text format     Abstract available


  146. FOLEY RW, Maweni RM, Gorman L, Murphy K, et al
    The ERSPC Risk Calculators Significantly Outperform The PCPT 2.0 In The Prediction Of Prostate Cancer; A Multi-Institutional Study.
    BJU Int. 2016 Feb 2. doi: 10.1111/bju.13437.
    PubMed     Text format     Abstract available


  147. YAP SA
    Should we worry about positive surgical margins in prostate cancer?
    BJU Int. 2016;117:207-8.
    PubMed     Text format    


    January 2016
  148. RUDMAN SM, Gray KP, Batista JL, Pitt MJ, et al
    Risk of prostate cancer specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence.
    BJU Int. 2016 Jan 25. doi: 10.1111/bju.13428.
    PubMed     Text format     Abstract available


  149. MADAN RA, Karzai FH, Ning YM, Adesunloye BA, et al
    Phase II Trial of Docetaxel, Bevacizumab, Lenalidomide, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer.
    BJU Int. 2016 Jan 18. doi: 10.1111/bju.13412.
    PubMed     Text format     Abstract available


  150. BOYLE P, Koechlin A, Bota M, d'Onofrio A, et al
    Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis.
    BJU Int. 2016 Jan 18. doi: 10.1111/bju.13417.
    PubMed     Text format     Abstract available


  151. STOREBJERG TM, Hoyer S, Kirkegaard P, Bro F, et al
    Prevalence of the HOXB13 G84E mutation in Danish men treated by radical prostatectomy and correlations with prostate cancer risk and aggressiveness.
    BJU Int. 2016 Jan 18. doi: 10.1111/bju.13416.
    PubMed     Text format     Abstract available


  152. BOKHORST LP, Lepisto I, Kakehi Y, Bangma CH, et al
    Complications after prostate biopsies in men on active surveillance and its effect on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.
    BJU Int. 2016 Jan 14. doi: 10.1111/bju.13410.
    PubMed     Text format     Abstract available


  153. FREEDLAND SJ, Howard LE, Hanyok BT, Kadiyala VK, et al
    Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer.
    BJU Int. 2016 Jan 13. doi: 10.1111/bju.13405.
    PubMed     Text format     Abstract available


  154. VELTRI RW
    Serum marker %[-2]proPSA and the Prostate Health Index improve diagnostic accuracy for clinically relevant prostate cancer.
    BJU Int. 2016;117:12-13.
    PubMed     Text format    


  155. EMBERTON M
    Doubling our precision of risk stratification in early prostate cancer: too good to be true?
    BJU Int. 2016;117:8-9.
    PubMed     Text format    


  156. CHANDRASEKAR T, Evans CP
    Salvage radical prostatectomy: a few good men.
    BJU Int. 2016;117:9-10.
    PubMed     Text format    


  157. WILLIAMS SB, Bozkurt Y, Achim M, Achim G, et al
    Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy: a step-by-step guide to exposure and efficiency.
    BJU Int. 2016;117:192-8.
    PubMed     Text format     Abstract available


    December 2015
  158. GILSON C, Sydes MR, Chowdhury S
    Will chemotherapy change the management of prostate cancer?
    BJU Int. 2015 Dec 22. doi: 10.1111/bju.13400.
    PubMed     Text format     Abstract available


  159. VAN LEEUWEN PJ, Stricker P, Hruby G, Kneebone A, et al
    68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    BJU Int. 2015 Dec 18. doi: 10.1111/bju.13397.
    PubMed     Text format     Abstract available


  160. EMBERTON M
    Are men who are biopsied without prior prostate magnetic resonance imaging getting substandard care?
    BJU Int. 2015;116:837-9.
    PubMed     Text format    


  161. HANSKE J, Meyer CP, Trinh QD
    How can we improve surgical outcomes?
    BJU Int. 2015;116:835-6.
    PubMed     Text format    


  162. ALBERTSEN PC
    Surgery is possible: now let's prove its superior efficacy!
    BJU Int. 2015;116:834-5.
    PubMed     Text format    


  163. BAHL A, Masson S, Malik Z, Birtle AJ, et al
    Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).
    BJU Int. 2015;116:880-7.
    PubMed     Text format     Abstract available


  164. NOVARA G, Ficarra V, Zattoni F, Fedeli U, et al
    Recourse to radical prostatectomy and associated short-term outcomes in Italy: a country-wide study over the last decade.
    BJU Int. 2015;116:862-7.
    PubMed     Text format     Abstract available


  165. MONTORSI F, Gandaglia G, Briganti A
    Long-term outcomes of robot-assisted radical prostatectomy: Where do we stand?
    BJU Int. 2015;116:845-6.
    PubMed     Text format    


  166. SCHMID M, Ghani KR, Choueiri TK, Sood A, et al
    An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer.
    BJU Int. 2015;116:911-9.
    PubMed     Text format     Abstract available


  167. TULIAO PH, Koo KC, Komninos C, Chang CH, et al
    Number of positive preoperative biopsy cores is a predictor of positive surgical margins (PSM) in small prostates after robot-assisted radical prostatectomy (RARP).
    BJU Int. 2015;116:897-904.
    PubMed     Text format     Abstract available


  168. MOORE CM, Azzouzi AR, Barret E, Villers A, et al
    Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
    BJU Int. 2015;116:888-96.
    PubMed     Text format     Abstract available


    November 2015
  169. ONG WL, Evans SM, Spelman T, Kearns PA, et al
    Comparison of oncological and health related quality of life (HRQOL) outcomes between open (ORP) and robotic-assisted radical prostatectomy (RARP) for localized prostate cancer - findings from the population-based Victorian Prostate Cancer Registry (P
    BJU Int. 2015 Nov 17. doi: 10.1111/bju.13380.
    PubMed     Text format     Abstract available


  170. ROLLE L, Falcone M, Ceruti C, Timpano M, et al
    A prospective multicentric international study on the surgical outcomes and patients' satisfaction rates of the "Sliding Technique" for end-stage Peyronie's disease with severe shortening of the penis and erectile dysfunction.
    BJU Int. 2015 Nov 11. doi: 10.1111/bju.13370.
    PubMed     Text format     Abstract available


  171. ALBERTSEN PC
    Does a positive margin always mandate adjuvant radiotherapy?
    BJU Int. 2015;116:677-8.
    PubMed     Text format    


  172. LOEB S, Ribal MJ
    Controversies in management of high-risk prostate and bladder cancer.
    BJU Int. 2015;116:675.
    PubMed     Text format    


  173. KUMAR A, Samavedi S, Bates AS, Coelho RF, et al
    Continence outcomes of robot-assisted radical prostatectomy in patients with adverse urinary continence risk factors.
    BJU Int. 2015;116:764-70.
    PubMed     Text format     Abstract available


  174. HSU CC, Paciorek AT, Cooperberg MR, Roach M 3rd, et al
    Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
    BJU Int. 2015;116:713-20.
    PubMed     Text format     Abstract available


  175. MELVIN JC, Garmo H, Daniel R, Shanmugalingam T, et al
    An investigation into the relationship between statins and cancer using population-based data.
    BJU Int. 2015;116:681-3.
    PubMed     Text format    


    October 2015
  176. MATSUSHITA K, Kent MT, Vickers AJ, von Bodman C, et al
    Preoperative predictive model of recovery of urinary continence after radical prostatectomy.
    BJU Int. 2015;116:577-83.
    PubMed     Text format     Abstract available


  177. SCOTT S, Samaratunga H, Chabert C, Breckenridge M, et al
    Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis.
    BJU Int. 2015;116 Suppl 3:26-30.
    PubMed     Text format     Abstract available


  178. MCCOMBIE SP, Hawks C, Emery JD, Hayne D, et al
    A 'One Stop' Prostate Clinic for rural and remote men: a report on the first 200 patients.
    BJU Int. 2015;116 Suppl 3:11-7.
    PubMed     Text format     Abstract available


  179. ROTH H, Millar JL, Cheng AC, Byrne A, et al
    The state of TRUS biopsy sepsis: readmissions to Victorian hospitals with TRUS biopsy-related infection over 5 years.
    BJU Int. 2015;116 Suppl 3:49-53.
    PubMed     Text format     Abstract available


  180. SUNDI D, Han M
    Brachytherapy for prostate cancer: feasible but oncological equivalence unproven.
    BJU Int. 2015;116 Suppl 3:89-91.
    PubMed     Text format    


    June 2015
  181. PARK J, Cho SY, Jeong SH, Lee SB, et al
    Low testosterone level is an independent risk factor for high-grade prostate cancer detection via biopsy.
    BJU Int. 2015 Jun 18. doi: 10.1111/bju.13206.
    PubMed     Text format     Abstract available


    May 2015
  182. CARLSSON S, Drevin L, Loeb S, Widmark A, et al
    Population-based study of long-term functional outcomes after prostate cancer treatment.
    BJU Int. 2015 May 8. doi: 10.1111/bju.13179.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: